Considering lymphoid malignancies, AFM13 is the first BiKE that specifically recruits NK cells through CD16A binding while targeting CD30, and which was given to relapsed or refractory Hodgkin lymphoma (R/R HL) patients. This evidence concerns the gene BMP2K and Hodgkins lymphoma.